PERJETA is indicated for use in combination with Herceptin® (trastuzumab) and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node-positive) as part of a complete treatment regimen for early breast cancer (EBC).1

Multiple studies have evaluated the efficacy and safety of PERJETA + Herceptin-based neoadjuvant therapy in patients with HER2+ breast cancer.

Learn about the trial designs, endpoints, and baseline characteristics

See data from multiple neoadjuvant studies

Review the adverse reactions in neoadjuvant trials

View the appropriate dosing schedule and duration of treatment

*Patients should discontinue treatment before 1 year if they experience disease recurrence or unmanageable side effects.

Patients who begin PERJETA and Herceptin in the neoadjuvant setting should receive 3-6 cycles before surgery and should continue treatment after surgery, every 3 weeks, to complete 1 year (up to 18 cycles).

Reference